scholarly journals Small Cell Carcinoma of the Gallbladder: Case Report and Comprehensive Analysis of Published Cases

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Carolyn Carrera ◽  
Paul Kunk ◽  
Osama Rahma
Keyword(s):  
Overall Survival ◽  
Case Report ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Metastatic Disease ◽  
Median Overall Survival ◽  
Case Reports ◽  
Small Cell ◽  
Carcinoma Of The Gallbladder ◽  
Local Disease

Background. Gallbladder small cell carcinoma is a rare and highly aggressive malignancy with no established standard of care treatment. We described here a case report of small cell gallbladder cancer and we then performed a comprehensive review of 72 case reports of this disease.Methods. Published case reports of small cell carcinoma of the gallbladder between 1983 and 2014 were reviewed. Treatment modalities and survival were analyzed for metastatic and localized disease.Results. Median overall survival for all patients was 13 months. Metastatic disease was identified in 72% of cases. Treatment of metastatic disease with chemotherapy showed a significant survival benefit (p<0.001) compared to no chemotherapy, and the use of platinum doublet with etoposide showed a nonsignificant 4-month improvement in survival compared to other chemotherapy regimens (p=0.13). Adjuvant therapy did not demonstrate an improvement of median overall survival in local disease (p=0.78).Conclusion. Given the limited available data, systemic therapy with platinum and etoposide should be considered for patients with metastatic small cell carcinoma of the gallbladder. Adjuvant chemoradiation or chemotherapy for treatment of local disease warrants further investigation.

scholarly journals A dural metastatic small cell carcinoma of the gallbladder as the first manifestation: a case report

2018 ◽  
Vol 16 (1) ◽  
Author(s):  
Shuichi Tonomura ◽  
Tomoko Kitaichi ◽  
Rina Onishi ◽  
Yoshiaki Kakehi ◽  
Hisao Shimizu ◽  
...  
Keyword(s):  
Case Report ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Carcinoma Of The Gallbladder

scholarly journals Small Cell Carcinoma Esophagus: Experience of an Indian Tertiary Cancer Center

2021 ◽  
Author(s):  
Goutam Santosh Panda ◽  
Vanita Noronha ◽  
Subhash Yadav ◽  
Amit Joshi ◽  
Vijay Patil ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Median Overall Survival ◽  
Local Therapy ◽  
Cranial Irradiation ◽  
Small Cell ◽  
Cancer Center ◽  
Carcinoma Of The Esophagus ◽  
Stage Disease

Abstract Background: Small cell carcinoma of the esophagus (SCCE) is a rare and aggressive tumor with no established standard treatment.Methods: This is a retrospective study of adult patients with histologically proven SCCE registered between February 2011 and March 2020 at Tata Memorial Hospital in Mumbai.Results: There were 56 patients with 29(51.8%) having limited-stage disease (LD) and 27(48.2%) having extensive-stage disease (ED). The median age was 58(IQR 51-65) years, 57.1% were men, 40% were smokers. Amongst LD-SCCE patients, 23 underwent local therapy i.e. radiation (19, 65.5%), surgery (4, 13.8%) and 27 received chemotherapy in neoadjuvant (23, 79.3%), concurrent (18, 62.1%) and adjuvant (4,13.8%) settings. Total 19 ED-SCCE patients (70.4%) received chemotherapy. Prophylactic cranial irradiation (PCI) was delivered to 11(37.9%) and 7(25.9%) patients with LD-SCCE and ED-SCCE, respectively. Significant grade ≥3 chemo-toxicities in patients with LD-SCCE and ED-SCCE included febrile neutropenia in 33.3% and 23.5%, anemia in 9.5% and 17.6%, and dyselectrolytemia in 14.3% and 11.8%, respectively. The median overall survival (OS) in LD-SCCE and ED-SCCE were 22.9 (95% CI 1.8-44.1) months and 11.8 (95% CI 7.3-16.4) months, respectively. Age <60years (p=0.004) and tumor epicenter in lower third esophagus (p=0.002) were good prognostic factors for OS in LD-SCCE and ED-SCCE patients respectively. The incidence of brain metastasis was low, both at presentation (1/27, 3.7%) and at relapse (5/56, 8.9%).Conclusion: Although the median overall survival of LD-SCCE is better than ED-SCCE, it is still under 2 years. Brain metastases are uncommon and PCI can be avoided with close clinico-radiological follow up.

scholarly journals Small Cell Carcinoma of the Gallbladder: 18F-FDG PET/CT Imaging Features—A Case Report

2010 ◽  
Vol 44 (3) ◽  
pp. 213-216 ◽  
Author(s):  
Da-Mi Kim ◽  
Seoung-Oh Yang ◽  
Hyun Young Han ◽  
Kyu Soon Kim ◽  
Hyun Jin Son
Keyword(s):  
Case Report ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Fdg Pet ◽  
Small Cell ◽  
Imaging Features ◽  
Carcinoma Of The Gallbladder ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Small Cell Carcinoma of the Gallbladder: A Case Report

2012 ◽  
Vol 16 (3) ◽  
pp. 266
Author(s):  
Hye Seon Shin ◽  
Young Hwan Lee ◽  
Se Woong Lim ◽  
See Sung Choi ◽  
Geum Ha Choi
Keyword(s):  
Case Report ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Carcinoma Of The Gallbladder

scholarly journals Small Cell Carcinoma Esophagus: Experience of an Indian Tertiary Cancer Center

2021 ◽  
Author(s):  
Goutam Santosh Panda ◽  
Vanita Noronha ◽  
Subhash Yadav ◽  
Amit Joshi ◽  
Vijay Patil ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Median Overall Survival ◽  
Local Therapy ◽  
Cranial Irradiation ◽  
Small Cell ◽  
Cancer Center ◽  
Carcinoma Of The Esophagus ◽  
Stage Disease

Abstract Background: Small cell carcinoma of the esophagus (SCCE) is a rare and aggressive tumor with no established standard treatment.Methods: This is a retrospective study of adult patients with histologically proven SCCE registered between February 2011 and March 2020 at Tata Memorial Hospital in Mumbai.Results: There were 56 patients with 29 (51.8%) having limited-stage disease (LD) and 27 (48.2%) having extensive-stage disease (ED). The median age was 58 (IQR 51-65) years, 57.1% were men, 40% were smokers. Amongst LD-SCCE patients, 23 underwent local therapy i.e. radiation (19, 65.5%), surgery (4, 13.8%) and 27received chemotherapy in neoadjuvant (23, 79.3%), concurrent (18, 62.1%) and adjuvant (4,13.8%) settings. Total 19 ED-SCCE patients (70.4%) received chemotherapy. Prophylactic cranial irradiation (PCI) was delivered to 11(37.9%) and 7(25.9%) patients with LD-SCCE and ED-SCCE, respectively. Significant grade ≥3 chemo-toxicities in patients with LD-SCCE and ED-SCCE included febrile neutropenia in 33.3% and 23.5%, anemia in 9.5% and 17.6%, and dyselectrolytemia in 14.3% and 11.8%, respectively. The median overall survival (OS) in LD-SCCE and ED-SCCE were 22.9 (95% CI 1.8-44.1) months and 11.8 (95% CI 7.3-16.4) months, respectively. Age <60years (p=0.004) and tumor epicenter in lower third esophagus (p=0.002) were good prognostic factors for OS in LD-SCCE and ED-SCCE patients respectively. The incidence of brain metastasis was low, both at presentation (1/27, 3.7%) and at relapse (5/56, 8.9%).Conclusion: Although the median overall survival of LD-SCCE is better than ED-SCCE, it is still under 2 years. Brain metastases are uncommon and the role of PCI is uncertain.

Small Cell Carcinoma Manifesting as a Bulky Thoracic Mass in a Pregnant Woman: A Case Report

2006 ◽  
Vol 55 (5) ◽  
pp. 477
Author(s):  
In Jae Lee ◽  
Kwang Seok Eom ◽  
Seon Young Jeon ◽  
Im Kyung Hwang ◽  
Yul Lee ◽  
...  
Keyword(s):  
Case Report ◽  
Pregnant Woman ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell

scholarly journals Small Cell Carcinoma of the Uterine Cervix in a Pregnant Patient Diagnosed with Liquid Based Cytology and Cell Block Immunocytochemistry

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Mawuli F. Attipoe ◽  
Charles D. Sturgis
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Uterine Cervix ◽  
Case Reports ◽  
Pregnant Patient ◽  
Small Cell ◽  
Tumor Type ◽  
Cell Block ◽  
Current Case ◽  
Small Series

Definitive cytomorphologic diagnosis of small cell carcinoma of the uterine cervix is possible but can be challenging in routine cervicovaginal cancer screening specimens. Several small series of reported cases of cervical small cell carcinoma have shown this uncommon malignancy to represent fewer than 2% of all invasive cervical cancers. This tumor type is associated with poor prognosis and rapid disease progression and can develop to an advanced stage in the interval between screening visits. Only rare case reports of small cell carcinoma arising in gravid cervices are known. In the current case a 29-year-old, gravida 6, para 2, pregnant (10-week gestation) female presented with postcoital bleeding. A definitive diagnosis of small cell carcinoma of the cervix was made possible by liquid based Pap testing with ancillary cell block preparation allowing for immunocytochemical characterization of the lesional cell population.

Long-Term Outcomes of Organ Preservation in Patients with Small Cell Carcinoma of the Bladder

2015 ◽  
Vol 94 (4) ◽  
pp. 401-405 ◽  
Author(s):  
Jairam R. Eswara ◽  
Niall M. Heney ◽  
Chin-Lee Wu ◽  
W. Scott McDougal
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Metastatic Disease ◽  
Advanced Disease ◽  
Chemical Exposure ◽  
Small Cell ◽  
Cancer Specific Survival ◽  
Entire Cohort ◽  
Aggressive Disease ◽  
Carcinoma Of The Bladder

Background: Small cell carcinoma of the bladder is an uncommon but clinically aggressive disease. There is no standard surgical or medical management for the disease. Methods: Between 1995 and 2009, 28 patients underwent transurethral resection (TUR) and/or cystectomy, chemotherapy, and/or radiation for small cell carcinoma of the bladder at our institution. Results: The median follow-up for survivors was 34 months. Patients presented most often with muscle-invasive disease (T2-4 - 89%), and 21% had lymph node/distant metastases. Tobacco use and chemical exposure were noted in 64 and 4% of patients, respectively. Patients with T1-2N0M0 had a median survival of 22 months compared to 8 months for those with more advanced disease (p = 0.03). Patients with T3-4 or nodal/metastatic disease who were given chemotherapy had an improved survival compared to those with T3-4 or nodal/metastatic disease who did not undergo chemotherapy (13 vs. 4 months, p = 0.005). The median time to recurrence of the entire cohort was 8 months, overall and cancer-specific survival was 14 months, and 5-year survival was 11%. Conclusions: Small cell carcinoma of the bladder is an aggressive disease with poor outcomes. Patients with T1-2N0M0 disease survived longer than those with advanced disease. Patients with T3-4 or nodal/metastatic disease had improved survival with chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document